A therapeutic trial of radiation therapy with vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas: An Eastern Cooperative Oncology Group Study (E2392)

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were ent...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 1998-03, Vol.37 (1), p.55-62
Main Authors: HELLMAN, R, NEUBERG, D. S, WAGNER, H, GRUNNET, M, ROBINS, H. L, KARP, D, FLYNN, P, ADAMS, G
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Astrocytoma - drug therapy
Astrocytoma - radiotherapy
Biological and medical sciences
Chemotherapy
Combined Modality Therapy
Etoposide - administration & dosage
Female
Glioblastoma - drug therapy
Glioblastoma - radiotherapy
Glioma - drug therapy
Glioma - radiotherapy
Humans
Infusions, Intravenous
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Procarbazine - administration & dosage
Prognosis
Survival Analysis
Vincristine - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
ISSN:0167-594X
1573-7373
DOI:10.1023/A:1005867520788